Clinical Trials Logo

Primary Amyloidosis clinical trials

View clinical trials related to Primary Amyloidosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02555969 Completed - Amyloidosis Clinical Trials

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

Start date: August 2015
Phase:
Study type: Observational

This protocol will assess patients with AL amyloidosis who achieve a complete response (CR) or very good partial response (VGPR) to therapy for minimal residual disease (MRD). Three approaches to MRD testing will be used since there is no established method. The investigators will clone and sequence each patient's light chain (LC) gene and design patient-specific primers to evaluate genomic DNA from future marrow specimens. Whole genome sequencing (WGS) will be used to test baseline and follow-up marrow cell DNA, seeking copy number variations in chromosomes 1 and 2 or 22, and structural variations in chromosomes 11 and 14, consistent with the known genetic abnormalities in AL and with clonal LC gene use. Plasma protein analysis by mass spectrometry will also be used to look for fragmentary protein sequences associated with the culprit LC gene of each subject. The feasibility and predictive value of these three approaches in patients achieving CR or VGPR will be evaluated. This protocol will help provide insight into the ways that the disease changes and progresses. MRD testing is likely an important next step in AL management.

NCT ID: NCT01707264 Completed - Primary Amyloidosis Clinical Trials

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Start date: April 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.

NCT ID: NCT00883623 Completed - Primary Amyloidosis Clinical Trials

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis

LEOMEX
Start date: April 2009
Phase: Phase 2
Study type: Interventional

The treatment with oral melphalan and prednisone has been recommended as standard treatment of AL amyloidosis but the results are rather disappointing. Another therapeutic option is pulsed high-dose dexamethasone + melphalan (Mel-Dex) with more encouraging results regarding the achievement of a faster disease response and higher rates of haematological remission. In the last 5 - 10 years, promising treatment outcomes after therapy with high-dose melphalan and autologous stem cell support have been reported by several groups but only highly selected patients are eligible for this treatment. Lenalidomide has been shown to be effective in phase II and III trials in MM patients. Because of the relationship to MM, Lenalidomide is a promising therapeutic option also for patients with AL amyloidosis. The addition of Lenalidomide to Mel-Dex could improve rate of complete response (CR) and organ response in patients not eligible for or refused high-dose chemotherapy.

NCT ID: NCT00807872 Completed - Primary Amyloidosis Clinical Trials

Radioimmunoimaging of AL Amyloidosis

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.

NCT ID: NCT00651937 Completed - Multiple Myeloma Clinical Trials

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan. Another goal of the study is to see how the dose of infused stem cells affects the levels of certain proteins in your blood. Researchers also want to learn how the dose of stem cells that you receive affects the quality of your life during the weeks after the transplant procedure.